Bronchodilator therapy in chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 2, 2000, Pages 99-103

  Manning, Harold L ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAMBUTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; OXITROPIUM BROMIDE; SALMETEROL; THEOPHYLLINE;

BRONCHODILATATION; CARDIOVASCULAR EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; METERED DOSE INHALER; NEBULIZATION; REVIEW;

EID: 0033818155     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200003000-00003     Document Type: Review

References (31)

1. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation
2. Breathlessness in patients with chronic airflow limitation. Mechanisms and management
3. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients
4. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease
5. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD
6. Utility of transfer factor to detect different bronchodilator responses in patients with chronic obstructive pulmonary disease
7. Theophylline for irreversible chronic airflow limitation A randomized study comparing n of 1 triats to standard practice
8. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease
9. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease
10. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
11. Efficacy of salmeterol xinafoate in the treatment of COPD
12. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease
13. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease
14. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease
15. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease
16. Effects of inhaled bronchodilators on pulmonary hemodynamics at rest and during exercise in patients with COPD
17. Efficacy of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD
18. Inhalation by nebulization of albuterol-ipratropium combination (Dey Combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease
19. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
20. For COPD, a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base
21. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD
22. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD
23. The effect of oral corticosteroids on bronchodilator responses in COPD
24. Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease
25. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
26. Anticholinergic versus β2-agonist on gas exchange in COPD: A comparative study in 15 patients
27. Acute effects of nebulized salbutamol on resting energy expenditure in patients with chronic obstructive pulmonary disease and in healthy subjects
28. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease
29. Starting home nebulizer therapy: Patients' expectations and subsequent outcome at 2 months
30. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: Influence of end-inspiratory pause
31. Inhaled fenoterol-ipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease